ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Characteristics of Patients with Idiopathic Pulmonary Fibrosis Admitted to Hospital: Data from the IPF-PRO Registry
Session Title
TP26 - TP026 DIAGNOSIS, ASSESSMENT, AND PROGNOSIS OF FIBROTIC ILD
Abstract
A1832 - Characteristics of Patients with Idiopathic Pulmonary Fibrosis Admitted to Hospital: Data from the IPF-PRO Registry
Author Block: M. E. Strek1, L. D. Snyder2, A. Adegunsoye1, M. L. Neely2, S. Bender3, E. S. White3, C. S. Conoscenti3, H. J. Kim4, on behalf of the IPF-PRO Registry investigators; 1Section of Pulmonary, Critical Care Medicine, University of Chicago, Chicago, IL, United States, 2Duke Clinical Research Institute, Durham, NC, United States, Duke University Medical Center, Durham, NC, United States, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States, 4University of Minnesota, Minneapolis, MN, United States.
Rationale: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF) and are associated with high mortality. The IPF-PRO Registry is a multicenter, observational registry of patients with IPF in the US. We used data from this registry to evaluate the characteristics of patients with IPF who were and were not hospitalized during follow-up. Methods: Patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. At the time of enrollment, retrospective data were collected from patients’ medical records. Patients were then followed prospectively, with follow-up data collected approximately every 6 months. Data for this analysis were extracted from the database in June 2020. In descriptive analyses, we examined the demographic and clinical characteristics of patients at enrollment among those who were and were not hospitalized during follow-up. Results: A total of 1002 patients were recruited at 46 sites. One hospitalized patient was excluded due to incomplete data. During a maximum follow-up of 67.0 months (median: 23.7 months), 550 patients (54.9%) were hospitalized. Most patients (74.5%) who were hospitalized had one (n=289; 52.5%) or two (n=121; 22.0%) hospitalizations during follow-up. The first hospitalization was respiratory-related in 45.5% of patients. Among those who were (n=550) and were not (n=451) hospitalized during follow-up, 26.9% and 20.0% of patients, respectively, had been hospitalized in the 12 months prior to enrollment. The demographic and clinical characteristics at enrollment of patients who were and were not hospitalized during follow-up in the registry are summarized in the Table. Compared with those who were not hospitalized, greater proportions of the patients who were hospitalized were former smokers (69.3% vs 59.9%), used oxygen at rest (22.4% vs 16.9%) and used oxygen with activity (38.5% vs 29.3%) at enrollment. Lung function at enrollment was similar in patients who were and were not hospitalized during follow-up: median FVC was 69.4% and 71.2% predicted and median DLco was 41.0% and 43.9% predicted in these groups, respectively. Conclusions: Fifty-five per cent of patients with IPF enrolled in the IPF-PRO Registry were hospitalized at least once during follow-up. Patients who were hospitalized during follow-up were more likely to be former smokers and to be using supplemental oxygen at enrollment than patients who were not hospitalized during follow-up.
Author Block: M. E. Strek1, L. D. Snyder2, A. Adegunsoye1, M. L. Neely2, S. Bender3, E. S. White3, C. S. Conoscenti3, H. J. Kim4, on behalf of the IPF-PRO Registry investigators; 1Section of Pulmonary, Critical Care Medicine, University of Chicago, Chicago, IL, United States, 2Duke Clinical Research Institute, Durham, NC, United States, Duke University Medical Center, Durham, NC, United States, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States, 4University of Minnesota, Minneapolis, MN, United States.
Rationale: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF) and are associated with high mortality. The IPF-PRO Registry is a multicenter, observational registry of patients with IPF in the US. We used data from this registry to evaluate the characteristics of patients with IPF who were and were not hospitalized during follow-up. Methods: Patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. At the time of enrollment, retrospective data were collected from patients’ medical records. Patients were then followed prospectively, with follow-up data collected approximately every 6 months. Data for this analysis were extracted from the database in June 2020. In descriptive analyses, we examined the demographic and clinical characteristics of patients at enrollment among those who were and were not hospitalized during follow-up. Results: A total of 1002 patients were recruited at 46 sites. One hospitalized patient was excluded due to incomplete data. During a maximum follow-up of 67.0 months (median: 23.7 months), 550 patients (54.9%) were hospitalized. Most patients (74.5%) who were hospitalized had one (n=289; 52.5%) or two (n=121; 22.0%) hospitalizations during follow-up. The first hospitalization was respiratory-related in 45.5% of patients. Among those who were (n=550) and were not (n=451) hospitalized during follow-up, 26.9% and 20.0% of patients, respectively, had been hospitalized in the 12 months prior to enrollment. The demographic and clinical characteristics at enrollment of patients who were and were not hospitalized during follow-up in the registry are summarized in the Table. Compared with those who were not hospitalized, greater proportions of the patients who were hospitalized were former smokers (69.3% vs 59.9%), used oxygen at rest (22.4% vs 16.9%) and used oxygen with activity (38.5% vs 29.3%) at enrollment. Lung function at enrollment was similar in patients who were and were not hospitalized during follow-up: median FVC was 69.4% and 71.2% predicted and median DLco was 41.0% and 43.9% predicted in these groups, respectively. Conclusions: Fifty-five per cent of patients with IPF enrolled in the IPF-PRO Registry were hospitalized at least once during follow-up. Patients who were hospitalized during follow-up were more likely to be former smokers and to be using supplemental oxygen at enrollment than patients who were not hospitalized during follow-up.
